Review

Mammalian models of extended healthy lifespan

Colin Selman and Dominic J. Withers

1 Institute of Biological and Environmental Sciences, University of Aberdeen, Aberdeen AB24 2TZ, UK
2 Metabolic Signalling Group, Medical Research Council Clinical Sciences Centre, Imperial College, London W12 0NN, UK

Over the last two centuries, there has been a significant increase in average lifespan expectancy in the developed world. One unambiguous clinical implication of getting older is the risk of experiencing age-related diseases including various cancers, dementia, type-2 diabetes, cataracts and osteoporosis. Historically, the ageing process and its consequences were thought to be intractable. However, over the last two decades or so, a wealth of empirical data has been generated which demonstrates that longevity in model organisms can be extended through the manipulation of individual genes. In particular, many pathological conditions associated with the ageing process in model organisms, and importantly conserved from nematodes to humans, are attenuated in long-lived genetic mutants. For example, several long-lived genetic mouse models show attenuation in age-related cognitive decline, adiposity, cancer and glucose intolerance. Therefore, these long-lived mice enjoy a longer period without suffering the various sequelae of ageing. The greatest challenge in the biology of ageing is to now identify the mechanisms underlying increased healthy lifespan in these model organisms. Given that the elderly are making up an increasingly greater proportion of society, this focused approach in model organisms should help identify tractable interventions that can ultimately be translated to humans.

Keywords: insulin signalling; ageing; nutrient sensing; target of rapamycin

1. INTRODUCTION

The last 200 years has seen an astonishing increase in human life expectancy in the developed world, with an estimated 30 years added to average life expectancy since the turn of the twentieth century [1]. This increase has been achieved through factors including better diet, cleaner water and significantly improved preventative medicine and palliative care [2]. The elderly are therefore making up a significantly greater proportion of the population, particularly when allied to low fertility and immigration [1]. Recent projections suggest that approximately 1.6 per cent of the UK population, compared with the current approximately 0.7 per cent, will be over 90 years of age by 2020 [3]. This means that if current trends continue, then the majority of babies born in the UK since 2000 will celebrate their 100th birthday [1]. These rapidly altering demographic profiles will have enormous social, economic and ethical implications because ageing is inexorably linked to physiological decline, loss of independence and decreased quality of life [4]. In particular, the prevalence of cardiovascular disease, dementia, cancer, sarcopenia, osteoporosis, osteoarthritis and type-2 diabetes all increase significantly with advancing age [4–6].

Obvious practical, ethical and economic obstacles exist to longitudinal studies investigating the determinants of human lifespan. Therefore, much effort in the biology of ageing has employed model organisms like yeast, the nematode worm Caenorhabditis elegans, the fruitfly Drosophila melanogaster and the mouse [2,7–9]. While it has been established for over 70 years that dietary restriction (DR) extends lifespan in many organisms [10–12], it has only been more recently that ageing and lifespan have been shown to be modulated by genetic factors [2,13–15]. Furthermore, many age-related pathophysiological processes relevant to the diseases of ageing in humans can be modelled in such organisms.

Specific mutations in the insulin/insulin-like growth factor (IGF) signalling (IIS) pathway extend lifespan in model organisms [7–9,13,16–19]. Polymorphisms in several IIS and growth hormone (GH)-related genes correlate with human longevity [20–22], and attenuated IIS may underlie the long life of GH/GH receptor-deficient dwarf mice (e.g. Ames (Prop1df/df), Snell (Pit1df/df)), Little (Ghrhrlit/lit), growth hormone receptor knockout (GHR-KO) [23]). The target of rapamycin (TOR) pathway also plays a key and conserved role in longevity control [24–29]. It is clear that understanding how exactly the IIS, GH and mTOR signalling pathways interact with one another to increase lifespan and healthspan is a key challenge to future research.

* Author for correspondence (d.withers@imperial.ac.uk).

One contribution of 15 to a Discussion Meeting Issue 'The new science of ageing'.
to age-related pathology (table 1). Our approach is effects on age-sensitive biomarkers and/or resistance of extended healthy lifespan through the positive of genetically modified mice demonstrating evidence this. This review will therefore examine those studies over this long life are crucial if we hope to achieve show both extended lifespan and improved health humans. Therefore, model organism studies that and consequently improve healthy lifespan in

The primary objective of biology of ageing research is to identify what underpins ageing in order to generate interventions that attenuate age-related pathology and consequently improve healthy lifespan in humans. Therefore, model organism studies that show both extended lifespan and improved health over this long life are crucial if we hope to achieve this. This review will therefore examine those studies of genetically modified mice demonstrating evidence of extended healthy lifespan through the positive effects on age-sensitive biomarkers and/or resistance to age-related pathology (table 1). Our approach is to describe in turn the various pathophysiological processes and diseases relevant to ageing in humans that are ameliorated in long-lived genetic mice. However, it should be noted that in many cases a limited number of pathologies have been examined, with relatively few long-lived mutants having undergone detailed examination in a broad range of disease parameters.

2. MUTATIONS IN INDIVIDUAL GENES THAT EXTEND HEALTHY LIFESPAN IN MAMMALS

(a) Maintenance of a youthful metabolic profile in long-lived mice

Ageing in humans is associated with greater adiposity, particularly visceral fat, higher body mass index and a significant loss in lean mass [30–32]. Commonly associated with these age-related changes in body composition are impairments in glucose tolerance and insulin sensitivity. Elevated adiposity and insulin resistance are significant risk factors for type-2 diabetes, coronary heart disease and stroke. In addition, insulin resistance is linked to higher colon, liver and pancreatic cancer incidence [33], more aggressive breast cancer tumours [34] and Alzheimer’s disease (AD) development [35]. The most widely studied phenotypic parameters in long-lived mice are those associated with body composition and glucose/insulin homeostasis. It is well established that long-lived GH/GH receptor dwarf mice are highly insulin sensitive [36–38]. Indeed, the absence of lifespan extension in GHR-KO mice following DR [36] or intermittent fasting [39] is suggested to be because these dietary interventions cannot further increase insulin sensitivity in these animals [40]. However, long-lived Snell dwarf mice are obese and hyperleptinaemic in old age [41], and have unaltered fasting (3–6 h) insulin and glucose levels relative to control mice at 20–23 months of age [41,42]. Percentage fat mass, normalized to total body mass, was also elevated in GHR-KO mice over a 2 year period relative to controls, with the increased adiposity more apparent in males [43]. Long-lived fat-specific insulin receptor knockout (FIRKO) mice are lean, have reduced total-body triglyceride levels and show resistance to age-related deterioration in glucose tolerance compared with wild-type (WT) controls [16]. Insulin receptor substrates 1 and 2 are key intracellular effectors of the IIS receptors [19]. Mice heterozygote for insulin receptor substrate 2 (Ins2+/−) have been described as long-lived in one study [44], but not in another despite

Table 1. Attenuated ageing-related decline in various phenotypic parameters in genetic mouse models of healthy ageing. (Long-lived genetic model and primary reference. 1, Homozygous ribosomal protein S6 kinase 1 knockout [29]; 2, homzygous insulin receptor substrate 1 knockout [19]; 3, homozygous fat-specific insulin receptor knockout [16]; 4, heterozygous insulin receptor substrate 2 knockout ([44], but see also [45]); 5, heterozygous insulin-like growth factor 1 receptor knockout [46]; 6, mutation of Prop1^{1/0} [122]; 7, mutation of Pit1^{Δ564/6} [41]; 8, homozygous growth hormone receptor (Laron) knockout [123]; 9, homozygous regulatory subunit of protein kinase A knockout [48]; 10, combined telomerase reverse transcriptase and p53, p16 and p19ARF transgenic [50]; 11, homozygous pregnancy-associated plasma protein A knockout [93]; 12, homozygous macrophage migration inhibitory factor knockout [94]; 13, homozygous type 5 adenyl cyclase knockout [68]; 14, mitochondrial targeted catalase transgenic [77]; 15, heterozygous glutathione peroxidase 4 knockout [74]; 16, metallothionein-IIa transgenic [79]; 17, homozygous mammalian proto-oncogene 66K knockout [80].)

| ref. | mouse model | phenotype parameter |
|------|-------------|---------------------|
| 1    | S6K1^{−/−}  | metabolism          |
| 2    | Ins1^{−/−}  | cognition           |
| 3    | FIRKO       | bone                |
| 4    | Ins2^{−/−}  | eye                 |
| 5    | Igs1r^{−/−} | heart               |
| 6    | Ames        | cancer              |
| 7    | Snell       | immunity            |
| 8    | GHR-KO      |                     |
| 9    | RIIβ        |                     |
| 10   | Sp53/Sp16/SArf/TgTert | + | + |
| 11   | PAPP-A-KO   |                     |
| 12   | MIF-KO      |                     |
| 13   | Acs5 KO     |                     |
| 14   | McAT        |                     |
| 15   | Gpx4^{+/−}  | +                   |
| 16   | MT          | +                   |
| 17   | p66^{−/−}   | +                   |

Phil. Trans. R. Soc. B (2011)
using the same mouse model [45]. Nonetheless, both male and female $\text{Irs2}^{+/−}$ mice were significantly more insulin sensitive at approximately 22 months of age relative to controls in the earlier study, despite no differences observed between genotypes at two months of age [44]. Reportedly, long-lived female mice heterozygote for the IGF-1 receptor ($\text{Igfr}^{+/−}$) ([46], but see also [47]) are also slightly more glucose tolerant compared with control animals [46]. Recently, we have shown that 600-day-old female mice null for ribosomal protein S6 kinase 1 ($\text{S6K1}^{−/−}$) are a downstream effector of mTOR signalling and IIS, are lean, hypeolectinaemic, glucose tolerant and insulin sensitive (assessed by the updated homeostasis model, HOMA2; [29]). These improvements are despite $\text{S6K1}^{−/−}$ mice being glucose intolerant at eight weeks of age [29].

Mice null for RIÎ², a regulatory subunit of protein kinase A, are long-lived, and resistant to both age-related obesity and hyperleptinaemia [48]. These mice also have lower fasting blood glucose levels at 24 months of age compared with WT littermates [48]. Male RIÎ² mutants were more insulin sensitive at young (two to five months) and old (18 months) ages relative to controls, although young females were not [48]. Studies examining the role of the cellular transmembrane protein, are long-lived but insulin sensitive (assessed by the updated homeostasis model, HOMA2; [29]). These improvements are despite $\text{S6K1}^{−/−}$ mice being glucose intolerant at eight weeks of age [29].

For example, female $\text{Irs1}^{−/−}$ mice at 450 days of age showed better motor/neurological function, as assessed by forced motor activity performance on a rotating rod (rotarod) apparatus, compared with WT mice [19]. Importantly, no improvement was seen in young (80-day-old) $\text{Irs1}^{−/−}$ mice, suggesting that the better rotarod performance in old age was not due to the dwarf phenotype. An enhancement in rotarod performance was also demonstrated in female $\text{S6K1}^{−/−}$ mice at 600 days of age [29]. In addition, these mice had enhanced overall general activity and exploratory drive performance during open-field testing at this age [29]. $\text{Sp53}^{−/−}$ mice at approximately 12 months of age also demonstrated better neuromuscular coordination during a tightrope test [50], and $\text{bIrs2}^{−/−}$ and $\text{bIrs2}^{−/−}$ mice were significantly more active than controls at 22 months of age [44].

Long-lived mice also appear more resistant to the sequelae of neurodegenerative conditions such as AD. For example, hippocampal slices from adult Ames mice are significantly more resistant to $\beta$-amyloid (Aβ) toxicity compared with controls [58]. AD is associated with altered neuronal insulin signalling [59], and several studies have investigated the effect of altered insulin signalling on AD progression. Mice expressing the Swedish mutation of amyloid precursor protein (APP$^{\text{Sw}}$, $\text{Tg2576}$) and crossed with long-lived bIGF1RKO$^{+/−}$ mice [18] were rescued from APP$^{\text{Sw}}$-induced early mortality and had significantly reduced Aβ accumulation at 60 weeks of age [59]. In addition, global IRS-2 deficiency in this AD model completely reversed early mortality and delayed Aβ accumulation [59]. In agreement, global IRS2 deficiency in APP$^{\text{Sw}}$ mice ameliorated Aβ pathology and improved several behavioural parameters despite increasing tau phosphorylation [60]. Interestingly, this is despite $\text{Irs2}^{−/−}$ mice of both sexes being significantly short-lived [19]. Mice expressing two AD-linked transgenes and crossed with $\text{Igfr}^{+/−}$ mice [46] were protected against several AD-related pathologies and impaired cognitive function [61]. Rapamycin, an inhibitor of the mTOR pathway, treatment significantly increases lifespan in mice [25] and was recently shown to attenuate cognitive deficits, Aβ pathology and tau pathology in two different AD mouse models [62,63].
(c) Delayed bone loss in long-lived mice
Osteoporosis, which clinically presents as reduced bone mass and altered bone structure, is a significant public health issue. For example, osteoporosis-related fractures, particularly hip fractures, are a major cause of morbidity and mortality in humans [64]. Clinical studies also suggest that there is overlap between several common disease mechanisms underlying osteoporosis and cardiovascular disease, including chronic inflammation, insulin resistance and obesity [65].

Mice also are prone to significant losses in bone volume with advancing age (e.g. [66]). Several studies examining long-lived mice have used a cross-sectional approach to show simultaneous preservation of bone function and quality with age. We have demonstrated, using micro-computed tomography, that female /mice at 450 and 700 days of age are resistant to age-related bone dysfunction [19]. /mice had greater cancellous bone volume, increased trabecular number and reduced trabecular separation compared with age-matched controls. Interestingly, this preservation in bone quality during ageing was seen despite young /mice being osteopenic [67]. Furthermore, using the same methodology, we recently showed that 600-day-old female /mice also had greater tibial bone volume and trabecular number compared with age-matched WT controls [29]. A preservation in bone volume with age was also reported in mice lacking type 5 adenylyl cyclase (AC5 KO), a key catalytic enzyme in the synthesis of cyclic adenosine monophosphate from adenosine triphosphate [68]. Female AC5 KO mice at 23 months of age had greater femoral bone density and calcification, less evidence of healing stress fractures and improved bone strength compared with controls [68]. Interestingly, tail tendons from young (four to eight months) and old (16–19 months) Snell mice are more resistant to urea-induced collagen denaturing, and Snell mice are protected against articular ageing and osteoarthritis [41,69]. Preservation of skeletal function during ageing is therefore often seen in long-lived mouse models.

(d) Attenuated visual deterioration in long-lived mice
Visual impairment and visual loss caused by several pathologies including macular degeneration, glaucoma and cataracts increase significantly in humans with advancing age [70]. These visual impairments may also exacerbate additional age-related pathologies including metabolic dysfunction, cardiovascular disease, insomnia, depression and impaired cognition through disruption in circadian photoreception [71].

Mice show comparable age-related increases in cataracts to humans, with similar regions of the lens affected. For example, C57BL/6 mice display a highly significant increase in the degree of cataract severity between six and 28 months of age [72]. Using a slit lamp protocol, it has been shown that both GHR-KO mice [72] and Snell dwarf mice [73] are resistant to age-related cataracts, with no differences in cataract levels relative to WT controls reported in GHR-KO mice at six months of age [72]. However, delayed cataract formation does not appear to be universal among long-lived mutant mice, as no difference was reported between long-lived glutathione peroxidase 4 heterozygous knockout mice (Gpx+/−) and controls at 25 months of age [74].

(e) Improved cardiac function in long-lived mice
Cardiovascular disease is a primary cause of mortality in humans worldwide, with its risk increasing significantly with advancing age [75]. Cardiovascular disease per se is not thought to be a prominent cause of mortality in most laboratory mouse strains. However, many of the age-related deteriorations in cardiovascular function observed in humans are also observed in mice [76]. Consequently, there is good evidence that aspects of cardiovascular ageing are significantly attenuated in long-lived mice.

It has been demonstrated that AC5 KO mice, for example, are resistant to age-related myocardial fibrosis and left ventricular (LV) hypertrophy [68]. These mice also have reduced cardiac apoptosis and smaller myocyte cross-sectional area at 20–30 months of age compared with WT mice. Male RIIβ null mice have preserved cardiac function and less evidence of LV hypertrophy at 24 months of age [48]. Long-lived mice over-expressing human catalase within their mitochondria (MCAT mice) [77] were also highly resistant to a range of cardiac-associated pathologies, including arteriosclerosis, cardiomyopathy, impaired diastolic function and LV hypertrophy at 20–25 months of age [76,77]. Interestingly, age-dependent cardiomyopathy in mice carrying a homozygous mutation in the exonuclease-encoding domain of mitochondrial polymerase gamma (Polg停工 mice) was ameliorated when Polg停工 mice were crossed with MCAT mice [78]. Transgenic mice over-expressing human metallothionein-IIa, a heavy metal-binding antioxidant, in cardiac tissue are long-lived and protected against both age-related diastolic dysfunction and decreased cardiac contractile reserve capacity [79]. Long-lived mice null for the cytoplasmic adaptor protein p66shc (p66停工停工) are long-lived [80] and resistant to age-dependent reactive oxygen species-mediated endothelial dysfunction [81]. p66停工停工 mice were protected against angiotensin II-induced LV hypertrophy, associated cardiomyocyte and endothelial cell apoptosis [82]. Long-lived mice null for either pregnancy-associated plasma protein A (PAPP-A-KO) [83], a metalloproteinase that degrades IGF-binding proteins, or p66停工停工 mice are protected against high fat diet-induced atherosclerosis when maintained in an apolipoprotein E-deficient (ApoeE) background.

(f) Protection against cancer in long-lived mice
Many cancers, including breast, prostate and colorectal, increase with advancing age, with the vast majority of cancer cases seen in people over 60 years of age [83]. The risk of mortality from cancer also increases in an age-dependent manner [85,86], although both incidence and mortality rate apparently plateau and subsequently decline after 90 years of age [86]. Cancer is the primary cause of death in most mouse strains, although tumour type appears highly strain specific [87]. For example, the C57BL/6 strain...
commonly used in ageing research is particularly prone to lymphosarcoma [74,88]. Significant effort has focused on whether interventions that extend lifespan impact on cancer incidence and progression, with most studies examining end of life pathology.

Several studies have investigated whether long-lived GH/GH receptor-deficient dwarf mice are protected against cancer [89,90]. In Ames dwarfs, age-related neoplastic disease was delayed and adenocarcinoma severity reduced despite the percentage of tumour-bearing mice at death being similar to WT mice [91]. However, tumour burden (the number of different tumours) in Ames mice was similar to controls [91]. In contrast, Snell dwarfs had significantly reduced age-related tumour burdens [89] and a non-significant trend ($p = 0.06$) for reduced lymphoma and mammary adenocarcinoma [73]. GHR-KO mice also had decreased tumour incidence, reduced tumour burden, less severe pulmonary adenocarcinomas and an age-related delay in fatal neoplastic diseases relative to controls [92].

A comprehensive examination by two pathologists reported that a similar percentage of $Gp{x4^-/-}$ and control mice (55–60%) had neoplastic disease, although an age-related delay in fatal lymphoma was seen in $Gp{x4^-/-}$ mice [74]. Gross pathological investigation of 23- to 28-month-old PAPP-A-KO mice revealed significantly reduced tumour burden and no evidence of multiple tumours unlike control mice [93]. $R{iI8^-/-}$ null mice had less lymphosarcoma and splenic tumours compared with controls, although no differences were observed in hepatic tumours [48]. MCAT mice had unaltered haematopoietic tumour incidence compared with WT controls, but a significant reduction in the severity and tumour burden of non-haematopoietic tumours was seen post-mortem [88]. Mice null for the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF-KO) showed less evidence of hemangiosarcomas compared with WT controls [94]. However, we observed no difference in macroscopic tumour incidence at death in female $S6k{1^-/-}$ compared with controls [29], in agreement with findings in $bGf{1RkO^-/-}$ mice [18]. Lifespan extension following rapamycin treatment in mice also did not alter the distribution in the presumptive causes of mortality in mice, including tumour incidence [25].

(g) **Youthful immune profile and reduced inflammation in long-lived mice**

The presence of a chronic inflammatory state in humans, e.g. elevated pro-inflammatory cytokines and local infiltration of assorted inflammatory cells, underlies several ageing-related diseases, including cancer [6,86]. In mice, alterations in T-cell populations (i.e. greater proportion of naive T cells relative to memory T cells) are predictive of both a resistance to various cancers [95] and longevity [96,97]. However, it should be noted that this assay may not specifically indicate improved immune function (e.g. resistance to infection). In addition, mouse ageing studies by their very nature tend to use specific pathogen-free environments to protect mice from infection. Therefore, under these experimental conditions, definitive measures of improved immune function are consequently difficult to assay. However, functional assays such as viral challenge may be useful in determining whether immune function is maintained in long-lived mice during ageing. Interestingly, intranasal inoculation with influenza (H1N1, PR8) actually increased mortality, increased weight loss and diminished innate immunity in male DR mice [98].

We previously reported that female $I{rs}{1^-/-}$ mice at 450 and 700 days of age [19] and female $S6k{1^-/-}$ mice at 600 days of age [29] had significantly fewer memory and more naive T cells relative to WT mice. This is suggestive of a more youthful immune profile in these animals. Interestingly, the age-related reduction in haematopoietic stem cell number linked to anaemia, impaired response to vaccination and tumourigenesis was reversed in old mice following rapamycin treatment [99].

Aged mice, like humans, are susceptible to several inflammatory pathologies, including dermatitis, gastritis, peritonitis and enteritis [50]. Both male and female $I{rs}{1^-/-}$ mice were completely resistant to the age-related ulcerative dermatitis observed in old C57BL/6 mice, whereas 25 per cent of WT mice were afflicted [19]. From 50 weeks of age onwards, long-lived $Sp{35/Sp16/SArr/TgTert}$ mice were protected against age-related thinning of their epidermis and subcutaneous fat layer [50]. These mice also had higher skin keratinocyte telomerase activity, longer hair bulge and interfollicular epidermal termineromes, and higher clonalogenic potential of epidermal stem cells at both young and old ages [50]. $Sp{53/Sp16/SArr/TgTert}$ mice also had preserved intestinal tract epithelia during ageing and enhanced resistance to dextran sodium sulphate-induced intestinal ulcers [50]. PAPP-A-KO mice at 18 months of age are resistant to age-dependent thymic atrophy, have a more youthful T-cell profile and bone marrow enriched with thymus-seeding progenitor cells compared with controls [100]. MCAT mice also showed a trend towards less severe systemic inflammation [88]. Aged (27–29 months) Snell dwarfs are resistant to age-related changes in T-cell subsets, with preservation of their immune cell function and fewer P-glycoprotein (anergic)-expressing splenic cells [41]. However, as mentioned previously, the relationship between immune function and ageing appears incredibly complex. For example, long-lived Ames dwarf mice actually show various manifestations of immunodeficiency, in particular those relating to thymic function [101].

3. **CONCLUSIONS**

The application of mouse models to help inform what mechanisms underlie healthy ageing in mammals has provided exciting insights into this process but remains experimentally challenging. However, it is evident that despite these paradigm-shifting experiments, we still have no definitive mechanistic explanation of the ageing process, although enhanced resistance to oxidative stress ([102,103] but see also [104,105]), increased xenobiotic metabolism [106,107], altered mitochondrial function [108,109] and enhanced...
autophagy [110,111], for example, may be key, and not mutually exclusive, candidate mechanisms. Ames dwarf mice, for example, have enhanced paraquat resistance and lower liver and lung F(2) isoprostane levels in old age (14–20 months) compared with controls [112]. Fibroblasts from GH-deficient mice are also highly stress resistance [113,114], with Snell dwarfs fibroblasts showing enhanced antioxidant and base excision repair capacity following combined serum deprivation and paraquat exposure [115]. Therefore, we suggest that it is critical to determine whether parameters including stress resistance and base excision repair capacity are also altered in an age-dependent manner in other long-lived mouse models. Certainly, other mechanisms are also likely to be at work and full consideration is beyond the scope of this review, but are well covered elsewhere (e.g [116–119]).

It is highly evident that using mammalian models to understand what underlies extended healthy lifespan is a rapidly expanding and competitive field of research. This is clearly indicated by the fact that seven long-lived genetic mouse models were described by 2003 [47] but over 20 models have been reported by 2009 [120]. The basic rationale for undertaking these long-term, demanding and expensive studies is to determine whether increased lifespan translates to increased healthspan in later life. Therefore, those studies that simultaneously measure lifespan, assay biomarkers predictive of lifespan [121] and examine age-related pathology are likely to be our best hope of identifying tractable interventions that can ultimately be applied to humans. In particular, we feel that future ageing studies should pay particular attention to late age health.

The authors are grateful to our co-workers and collaborators for their extensive contributions to our research. In addition, D.J.W. is grateful to the Wellcome Trust (Functional Genomics Award and Strategic Award), the Medical Research Council and Research into Ageing. D.J.W. and C.S. recognize support from the Biological and Genomics Award and Strategic Award), the Medical Foundation for their extensive contributions to our research. In addition, The authors are grateful to our co-workers and collaborators for their extensive contributions to our research.

**REFERENCES**

1 Christensen, K., Doblhammer, G., Rau, R. & Vaupel, J. W. 2009 Ageing populations: the challenges ahead. *Lancet* **374**, 1196–1208. (doi:10.1016/S0140-6736(09)61460-4)

2 Partridge, L. 2010 The new biology of ageing. *Phil. Trans. R. Soc. B* **365**, 147–154. (doi:10.1098/rstb.2009.0222)

3 Tomassini, C. 2005 The demographic characteristics of the oldest old in the United Kingdom. *Popul. Trends** **120**, 15–22.

4 Vaupel, J. W. 2010 Biodemography of human ageing. *Nature** **464**, 536–542. (doi:10.1038/nature08984)

5 Bishop, N. A., Lu, T. & Yankner, B. A. 2010 Neural mechanisms of ageing and cognitive decline. *Nature** **464**, 529–535. (doi:10.1038/nature08983)

6 Sarkar, D. & Fisher, P. B. 2006 Molecular mechanisms of aging-associated inflammation. *Cancer Lett.** **236**, 13–23. (doi:10.1016/j.canlet.2005.04.009)

7 Broughton, S. & Partridge, L. 2009 Insulin/IGF-like signalling, the central nervous system and ageing. *Biochem. J.** **418**, 1–12. (doi:10.1042/BJ20082102)

8 Kenyon, C. J. 2010 The genetics of ageing. *Nature* **464**, 504–512. (doi:10.1038/nature08980)

9 Piper, M. D., Selman, C., McElwee, J. J. & Partridge, L. 2008 Separating cause from effect: how does insulin/IGF signalling control lifespan in worms, flies and mice? *J. Intern. Med.** **263**, 179–191. (doi:10.1111/j.1365-2796.2007.01906.x)

10 Masoro, E. J. 2005 Overview of caloric restriction and ageing. *Mech. Ageing Dev.** **126**, 913–922. (doi:10.1016/j.mad.2005.03.012)

11 McCay, C. M., Crowell, L. A. & Maynard, L. A. 1935 The effect of retarded growth upon the length of life and upon the ultimate body size. *J. Nutr.** **10**, 63–79.

12 Weindruch, R. & walford, R. L. 1988 *The retardation of ageing and disease by dietary restriction*. Springfield, IL: Charles C. Thomas.

13 Kenyon, C. 2005 The plasticity of ageing: insights from long-lived mutants. *Cell** **120**, 449–460. (doi:10.1016/j.cell.2005.02.002)

14 Partridge, L. & Gems, D. 2007 Benchmarks for ageing studies. *Nature* **450**, 165–167. (doi:10.1038/450165a)

15 Vijg, J. & Campisi, J. 2008 Puzzles, promises and a cure for ageing. *Nature* **454**, 1065–1071. (doi:10.1038/nature07216)

16 Blüher, M., Kahn, B. B. & Kahn, C. R. 2003 Extended longevity in mice lacking the insulin receptor in adipose tissue. *Science** **299**, 572–574. (doi:10.1126.science.1078223)

17 Clancy, D. J., Gems, D., Harshman, L. G., Oldham, S., Stocker, H., Hafen, E., Levers, S. J. & Partridge, L. 2001 Extension of life-span by loss of CHICO, a *Drosophila* insulin receptor substrate protein. *Science** **292**, 104–106. (doi:10.1126/science.1057991)

18 Kappeler, L. et al. 2008 Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. *PLoS Biol.** **6**, e254. (doi:10.1371/journal.pbio.0060254)

19 Selman, C. et al. 2008 Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. *FASEB J.** **22**, 807–818. (doi:10.1096/fj.07-9261com)

20 Pawlikowska, L. et al. 2009 Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. *Aging Cell** **8**, 460–472. (doi:10.1111/j.1477-9558.2009.00493.x)

21 Suh, Y., Azizm, G., Cho, M. O., Hwang, D., Liu, B., Leahy, D. J., Barzilai, N. & Cohen, P. E. 2005 Functionally significant insulin-like growth factor I receptor mutations in centenarians. *Proc. Natl Acad. Sci. USA** **102**, 3438–3442. (doi:10.1073/pnas.0705467105)

22 van Heemst, D., Beeckman, M., Mooijaart, S. P., Heijmans, B. T., Brandt, B. W., Zwaan, B. J., Slagboom, P. E. & Westendorp, R. G. 2005 Reduced insulin/IGF-1 signalling and human longevity. *Aging Cell** **4**, 79–85. (doi:10.1111/j.1477-9558.2005.00148.x)

23 Masternak, M. M., Panici, J. A., Bonkowski, M. S., Hughes, L. F. & Bartke, A. 2009 Insulin sensitivity as a key mediator of growth hormone actions on longevity. *J. Gerontol. A Biol. Sci. Med. Sci.** **64**, 516–521. (doi:10.1093/gerona/glp024)

24 Biedov, I., Toivonen, J. M., Kerr, F., Slack, C., Jacobson, J., Foley, A. & Partridge, L. 2010 Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab.** **11**, 35–46. (doi:10.1016/j.cmet.2009.11.010)

25 Harrison, D. E. et al. 2009 Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature** **460**, 392–395. (doi:10.1038/nature08221)

26 Kaeberlein, M. 2010 Resveratrol and rapamycin: are they anti-aging drugs? *Bioessays** **32**, 96–99. (doi:10.1002/bies.200900171)

*Phil. Trans. R. Soc. B* (2011)
Review. Extended healthy lifespan in mammals

74 Ran, Q., Liang, H., Ikeno, Y., Qi, W., Prolla, T. A., Roberts, V., Vergara, M., Smith-Wheelock, M., Harper, J. M., Wolf, N., Penn, P., Pendergrass, W., Van Remmen, H., Killick, R., et al. 2009 Deletion of Irs2 reduces amyloid deposition and rescues behavioral deficits in APP transgenic mice. Biochem. Biophys. Res. Commun. 386, 257–262. (doi:10.1016/j.bbrc.2009.06.032)

62 Cohen, E. et al. 2009 Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157–1169. (doi:10.1016/j.cell.2009.11.014)

52 Caccamo, A., Majumder, S., Richardson, A., Strong, R. & Oddo, S. 2010 Molecular interplay between mTOR, amyloid-β, and Tau: effects on cognitive impairments. J. Biol. Chem. 285, 13107–13120. (doi:10.1074/jbc.M110.110420)

41 Spilman, P., Podlutksaya, N., Hart, M. J., Deb Nath, J., Caccamo, A., Majumder, S., Richardson, A., Strong, R., Garcia, M., Galvan, V. 2010 Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. PLoS ONE 5, e9979. (doi:10.1371/journal.pone.0009979)

34 Khosla, S. 2010 Update in male osteoporosis. J. Clin. Endocrinol. Metab. 95, 3–10. (doi:10.1210/jc.2009-1740)

25 Crepaldi, G. & Maggi, S. 2009 Epidemiologic link between osteoporosis and cardiovascular disease. J. Endocrinol. Invest. 32, 2–5.

16 Halloran, B. P., Ferguson, V. L., Simske, S. J., Harrington, S. C., Simari, R. D. & Conover, C. A. 2007 Type 5 adenylyl cyclase disruption of age-associated proteotoxicity in mice. JCI9017) (doi:10.1172/JCI9017)

8 Yan, L. et al. 2007 Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130, 247–258. (doi:10.1016/j.cell.2007.05.038)

76 Dai, D. F. et al. 2009 Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 119, 2789–2797. (doi:10.1161/CIRCULATIONAHA.109.104017)

75 Murray, C. J. & Lopez, A. D. 1997 Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349, 1269–1276. (doi:10.1016/S0140-6736(96)70493-4)

69 Yang, X., Doser, T. A., Fang, C. X., Nunn, J. M., Janardhanan, R., Zhu, M., Sreejayan, N., Quinn, M. T. & Ren, J. 2006 Metallothionein IIb prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: role of oxidative stress. FASEB J. 20, 1024–1026. (doi:10.1096/fj.05-5288fje)

68 Migliazzo, R., Giorgio, M., Mele, S., Pelicci, G., Reboldi, P., Pandolfi, P. P., Lanfrancone, L. & Pelicci, P. G. 1999 The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309–313. (doi:10.1038/46311)

67 Francia, P. et al. 2004 Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 110, 2889–2895. (doi:10.1161/01.CIR.0000147731.24444.4D)

66 Grianti, G. et al. 2005 Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. Hypertension 46, 433–440. (doi:10.1161/01.HYP.0000174986.73346.ba)

65 Harrington, S. C., Simari, R. D. & Conover, C. A. 2007 Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ. Res. 100, 1696–1702. (doi:10.1161/CIRCRESAHA.106.146183)

64 Napol, C. et al. 2003 Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc. Natl Acad. Sci. USA 100, 2112–2116. (doi:10.1073/pnas.0235910100)

63 Ahmad, A., Banerjee, S., Wang, Z., Kong, D., Majumdar, A. P. & Sarkar, F. H. 2009 Aging and inflammation: etiological culprits of cancer. Curr. Aging Sci. 2, 174–186. (doi:10.2174/1874690810902030174)

62 Vasto, S., Carruba, G., Lio, D., Colonna-Romano, G., Di Bonà, D., Candore, G. & Caruso, C. 2009 Inflammation, ageing and cancer. Mech. Ageing Dev. 130, 40–45. (doi:10.1016/j.mad.2008.06.003)

61 Anisimov, V. N. 2001 Mutant and genetically modified mice as models for studying the relationship between aging and carcinogenesis. Mech. Ageing Dev. 122, 1221–1225. (doi:10.1016/S0025-4709(01)00262-7)

60 Treuting, P. M., Linford, N. J., Knoblaugh, S. E., Emond, M. J., Morton, J. F., Martin, G. M., Rabinovitch, P. S. & Ladiges, W. C. 2008 Reduction of age-associated pathology in old mice by overexpression of catalase targeted to mitochondria. J. Gerontol. A Biol. Sci. Med. Sci.63, 813–822.

59 Alderman, J. M. et al. 2009 Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice. Exp. Gerontol. 44, 26–33. (doi:10.1016/j.exger.2008.05.014)

58 Schrag, M., Sharma, S., Brown-Borg, H. & Ghribi, O. 2008 Hippocampus of Ames dwarf mice is resistant to beta-amyloid-induced tau hyperphosphorylation and changes in apoptosis-regulatory protein levels. Hippocampus 18, 239–244. (doi:10.1002/hipo.20387)
calorie-restricted mice share common anti-aging mechanisms—a pathological point of view. *Age (Dordr).* 28, 163–171. (doi:10.1007/s11377-006-9007-7)

91 Ikeno, Y., Bronson, R. T., Hubbard, G. B., Lee, S. & Bartke, A. 2003 Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. *J. Gerontol. A Biol. Sci. Med. Sci.* 58, 291–296. (doi:10.1093/gerona/glp017)

92 Ikeno, Y. et al. 2009 Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. *J. Gerontol. A Biol. Sci. Med. Sci.* 64, 522–529.

93 Conover, C. A. & Bale, L. K. 2007 Loss of pregnancy-associated plasma protein A extends lifespan in mice. *Aging Cell* 6, 727–729. (doi:10.1111/j.1474-9792.2007.00328.x)

94 Harper, J. M., Wilkinson, J. E. & Miller, R. A. 2010 Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. *FASEB J.* 24, 2436–2442. (doi:10.1096/fj.09-152223)

95 Miller, R. A. & Chrisp, C. 2002 T cell subset patterns that predict resistance to spontaneous lymphoma, mammary adenocarcinoma, and fibrosarcoma in mice. *J. Immunol.* 169, 1619–1625.

96 Miller, R. A. 2001 Biomarkers of aging: prediction of longevity by using age-sensitive T-cell subset determinations in a middle-aged, genetically heterogeneous mouse population. *J. Gerontol. A Biol. Sci. Med. Sci.* 56, B180–B186.

97 Miller, R. A., Chrisp, C. & Galecki, A. 1997 CD4 memory T cell subset predicts life span in genetically heterogeneous mice. *FASEB J.* 11, 775–783.

98 Ritz, B. W., Axtman, I., Nogusa, S. & Gardner, E. M. 2008 Energy restriction impairs natural killer cell function and increases the severity of influenza infection in young adult male C57BL/6 mice. *J. Nutr.* 138, 2269–2275. (doi:10.3945/jn.108.093633)

99 Chen, C., Liu, Y. & Zheng, P. 2009 mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. *Sci. Signal.* 2, ra75. (doi:10.1126/scisignal.2000559)

100 Vallejo, A. N., Michel, J. J., Bale, L. K., Lemster, B. H., Borghesi, L. & Conover, C. A. 2009 Resistance to age-dependent thymic atrophy in long-lived mice that are deficient in pregnancy-associated plasma protein A. *Proc. Natl Acad. Sci. USA* 106, 11 252–11 257. (doi:10.1073/pnas.0807025106)

101 Duquesnoy, R. J. 1972 Immunodeficiency of the thymus-dependent system of the Ames dwarf mouse. *J. Immunol.* 108, 1578–1590.

102 Golden, T. R., Hinerfeld, D. A. & Melov, S. 2002 Oxidative stress and aging: beyond correlation. *Aging Cell* 1, 117–123. (doi:10.1046/j.1474-9728.2002.00015.x)

103 Hagen, T. M. 2003 Oxidative stress, redox imbalance, and the aging process. *Antioxid. Redox Signal.* 5, 503–506. (doi:10.1089/15230860377031049)

104 Gems, D. & Doonan, R. 2009 Antioxidant defense and aging in C. elegans: is the oxidative damage theory of aging wrong? *Cell Cycle* 8, 1681–1687.

105 Perez, V. I., Bokov, A., Van Remmen, H., Mele, J., Ran, Q., Ikeno, Y. & Richardson, A. 2009 Is the oxidative stress theory of aging dead? *Biochim. Biophys. Acta* 1790, 1005–1014.

106 Gems, D. & McElwee, J. J. 2005 Broad spectrum detoxification: the major longevity assurance process regulated by insulin/IGF-1 signaling? *Mech. Aging Dev.* 126, 381–387. (doi:10.1016/j.mad.2004.09.001)

107 McElwee, J. J. et al. 2007 Evolutionarily conservation of regulated longevity assurance mechanisms. *Genome Biol.* 8, R132. (doi:10.1186/gb-2007-8-7-r132)

108 Balaban, R. S., Nemoto, S. & Finkel, T. 2005 Mitochondria, oxidants, and aging. *Cell* 120, 483–495. (doi:10.1016/j.cell.2005.02.001)

109 Van Remmen, H. & Jones, D. P. 2009 Current thoughts on the role of mitochondria and free radicals in the biology of aging. *J. Gerontol. A Biol. Sci. Med. Sci.* 64, 171–174.

110 Cuervo, A. M., Bergamini, E., Brunk, U. T., Droge, W., Fremen, M. & Terman, A. 2005 Autophagy and aging: the importance of maintaining ‘clean’ cells. *Autophagy* 1, 131–140. (doi:10.4161/auto.1.3.2017)

111 Terman, A., Gustafsson, B. & Brunk, U. T. 2007 Autophagy, organelles and ageing. *J. Pathol.* 211, 134–143. (doi:10.1002/path.2094)

112 Bokov, A. F., Lindsey, M. L., Khodr, C., Sabia, M. R. & Richardson, A. 2009 Long-lived Ames dwarf mice are resistant to chemical stressors. *J. Gerontol. A Biol. Sci. Med. Sci.* 64, 819–827. (doi:10.1093/gerona/glp052)

113 Murakami, S., Salmon, A. & Miller, R. A. 2003 Multiplex stress resistance in cells from long-lived dwarf mice. *FASEB J.* 17, 1565–1566.

114 Salmon, A. B., Murakami, S., Bartke, A., Kopchick, J., Yasumura, K. & Miller, R. A. 2005 Fibroblast cell lines from young adult mice of long-lived mutant strains are resistant to multiple forms of stress. *Am. J. Physiol. Endocrinol. Metab.* 289, E23–E29. (doi:10.1152/ajpendo.00575.2004)

115 Page, M. M., Salmon, A. B., Leiser, S. F., Robb, E. L., Brown, M. F., Miller, R. A. & Stuart, J. A. 2009 Mechanisms of stress resistance in Snell dwarf mouse fibroblasts: enhanced antioxidant and DNA base excision repair capacity, but no differences in mitochondrial metabolism. *Free Radic. Biol. Med.* 46, 1109–1118. (doi:10.1016/j.freeradbiomed.2009.01.014)

116 Campisi, J. 2005 Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. *Cell* 120, 513–522. (doi:10.1016/j.cell.2005.02.003)

117 Kirkwood, T. B. 2005 Understanding the odd science of aging. *Cell* 120, 437–447. (doi:10.1016/j.cell.2005.01.027)

118 Lombard, D. B., Chua, K. F., Mostoslavsky, R., Franco, S., Gostissa, M. & Alt, F. W. 2005 DNA repair, genome stability and aging. *Cell* 120, 497–512. (doi:10.1016/j.cell.2005.01.028)

119 Partridge, L., Gems, D. & Withers, D. J. 2005 Sex and death: what is the connection? *Cell* 120, 461–472. (doi:10.1016/j.cell.2005.01.026)

120 Ladiges, W., Van Remmen, H., Strong, R., Ikeno, Y., Treuting, P., Rabinovitch, P. & Richardson, A. 2009 Lifespan extension in genetically modified mice. *Aging Cell* 8, 346–352. ( doi:10.1111/j.1474-9726.2009.00491.x)

121 Ingram, D. K., Nakamura, E., Smucny, D., Roth, G. S. & Lane, M. A. 2001 Strategy for identifying biomarkers of aging in long-lived species. *Exp. Gerontol.* 36, 1025–1034. (doi:10.1016/S0531-5555(01)00110-3)

122 Brown-Borg, H. M., Borg, K. E., Meliska, C. J. & Bartke, A. 1996 Dwarf mice and the aging process. *Nature* 384, 33. (doi:10.1038/384033a0)

123 Coschigano, K. T., Cleemons, D., Bellush, L. L. & Kopchick, J. J. 2000 Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. *Endocrinology* 141, 2608–2613. (doi:10.1210/en.141.7.2608)